Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

J. Slamon, Dennis; Leyland‐Jones, Brian; Shak, Steven; Fuchs, H.; Paton, Virginia; Bajamonde, Alex; Fleming, Thomas; Eiermann, W.; Wolter, Janet; D. Pegram, Mark; Baselga, José; Norton, Larry

doi:10.1056/nejm200103153441101

Public

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

Published in New England Journal of Medicine • Mar 15, 2001

Authors:

Dennis J. Slamon

Brian Leyland‐Jones

Steven Shak

Abstract

BACKGROUND: The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 percent of breast cancers, increasing the aggressiveness of the tumor. METHODS: We evaluated the efficacy and safety of trastuzumab, a recombinant monoclonal antibody against ...

Subject

Medicine

Trastuzumab

Epirubicin

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!